Table 2.
Participants aged 33–44 years |
Participants aged 45–76 years |
|||||||||
---|---|---|---|---|---|---|---|---|---|---|
SMART (N=287*) |
CARDIA (N=3231†) |
% Diff.‡ (P-value) |
SMART (N=494§) |
MESA (N=5386) |
% Diff.‡ (P-value) |
|||||
Median |
IQR |
Median |
IQR |
Median |
IQR |
Median |
IQR |
|||
hsCRP (μg/mL) | 2.12 | 0.80–4.77 | 1.36 | 0.53–3.78 | 55.2 (<0.001) | 2.68 | 1.07–6.01 | 2.17 | 0.94–4.70 | 49.6 (<0.001) |
IL-6 (pg/mL) | 2.09 | 1.26–3.49 | 1.29 | 0.80–2.07 | 62.1 (<0.001) | 2.63 | 1.63–4.18 | 1.23 | 0.79–1.92 | 151.6 (<0.001) |
D-dimer (μg/mL) | 0.29 | 0.17–0.55 | NA | NA | NA | 0.34 | 0.20–0.61 | 0.20 | 0.13–0.35 | 94.3 (<0.001) |
Cystatin C (mg/dl) | 0.94 | 0.82–1.07 | NA | NA | NA | 1.00 | 0.88–1.17 | 0.85 | 0.76–0.96 | 27.2 (<0.001) |
NA = not available
172 had cystatin C measurements.
689 had IL-6 measurements.
% difference in means of log transformed value, adjusted for age, race, gender, BMI, smoking, total/HDL cholesterol, diabetes, lipid-lowering therapy and blood pressure lowering therapy.
231 had cystatin C measurements.